|
Efficacy and safety results in patients with impaired renal and hepatic function in the RECOURSE trial. |
|
|
Honoraria - Taiho Pharmaceutical |
Consulting or Advisory Role - CASI Pharmaceuticals |
|
|
|
Research Funding - Bristol-Myers Squibb |
|
|
Research Funding - Sumitomo Dainippon |
|
|
Honoraria - Amgen; Bayer; EMD Serono; Lilly; Merck; Roche; Sanofi |
Consulting or Advisory Role - Amgen; Bayer; EMD Serono; Lilly; Merck; Roche; Sanofi |
Speakers' Bureau - Amgen; Bayer; EMD Serono; Lilly; Merck; Roche; Sanofi |
Research Funding - Amgen (Inst); Bayer (Inst); EMD Serono (Inst); Lilly (Inst); Merck (Inst); Roche (Inst); Sanofi (Inst) |
|
|
Honoraria - Amgen (I); Boehringer Ingelheim (I); Lilly (I); Merck (I); Novartis (I); Pfizer (I); Roche (I) |
Consulting or Advisory Role - Boehringer Ingelheim (I); Lilly (I); Pfizer (I); Roche (I) |
|
Travel, Accommodations, Expenses - Amgen; Boehringer Ingelheim (I); Ipsen; Lilly (I); Merck; Novartis; Pfizer; Pfizer (I); Roche; Roche (I); Sanofi |
|
|
Travel, Accommodations, Expenses - Bayer |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
|
Consulting or Advisory Role - Multiple pharmaceutical/biotech companies |
|
|
No Relationships to Disclose |
|
|
Honoraria - Bayer; Chugai Pharma; Daiichi Sankyo; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical |
Research Funding - Lilly (Inst); Merck Serono (Inst); Taiho Pharmaceutical (Inst) |
|
|
Honoraria - Bayer; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo; Merck Serono; Taiho Pharmaceutical; Takeda; Yakult Honsha |
Research Funding - Bristol-Myers Squibb Japan (Inst) |
|
|
Honoraria - Bayer; Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical |
Speakers' Bureau - Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Kyowa Hakko Kirin; Lilly; Merck Serono; Novartis; Pfizer; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical |
Research Funding - Bayer (Inst); Bristol-Myers Squibb (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Yakult Pharmaceutical (Inst) |
|
|
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Genentech; Sirtex Medical |
Speakers' Bureau - Genomic Health |
|
|
Honoraria - Bayer; Boehringer Ingelheim; Celgene; Merck Serono; Roche |
Consulting or Advisory Role - Bayer; Merck Serono; Roche |
Travel, Accommodations, Expenses - Bayer; Merck Serono; Roche |
|
|
Honoraria - Astellas Pharma; Janssen-Cilag; Sanofi; Tolmar |
Consulting or Advisory Role - Amgen; Astellas Pharma; Bayer; Sanofi; Tolmar |
Research Funding - Amgen (Inst); Astellas Pharma (Inst); Genentech (Inst); Janssen-Cilag (Inst); Pfizer (Inst) |
Travel, Accommodations, Expenses - Amgen; Astellas Pharma |
|
|
No Relationships to Disclose |
|
|
Employment - Taiho Pharmaceutical |
|
|
Employment - Taiho Pharmaceutical |
|
|
Research Funding - amgen (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Ipsen (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Roche (Inst); Sanofi (Inst) |